Our Services
Medical Information
Helpful Resources
Published on: 3/9/2026
There are several factors to consider; for many paying out of pocket Farxiga can run about $500 to $650 per month, while insured costs can be $0 to $150 or even full price depending on coverage and assistance, reflecting its brand-only status, strong heart and kidney benefits, and the U.S. pricing system. See below to understand more.
If the price is a barrier, safe next steps include talking with your doctor before stopping or switching, checking your plan for formulary tier and prior authorization, using manufacturer savings or patient assistance, and discussing alternatives; see the complete guidance below because details can change the best choice for your situation.
If you've looked up the Farxiga price recently, you may have felt sticker shock. Farxiga (dapagliflozin) is a brand-name prescription medication used to treat:
It belongs to a class of drugs called SGLT2 inhibitors, which help the body remove excess glucose through the urine and provide heart and kidney protection beyond blood sugar control.
So, is the Farxiga price too high? The honest answer: for many people paying out of pocket, it can be expensive. But the actual cost varies widely depending on insurance coverage, location, and eligibility for assistance programs.
Let's break it down clearly and discuss medically appropriate next steps.
Without insurance, the retail Farxiga price in the United States can range from $500 to $650 per month for a 30-day supply (10 mg tablets), depending on the pharmacy.
However, what you actually pay may be very different.
Your out-of-pocket cost depends on:
For insured patients, monthly costs may range from:
Because Farxiga is still brand-name (not generic in the U.S. at the time of writing), the price remains high compared to older diabetes medications like metformin.
Several factors influence pricing:
Farxiga is manufactured by AstraZeneca and remains under patent protection. Without generic competition, brand-name pricing remains elevated.
Farxiga has undergone extensive clinical trials not only for diabetes but also for:
These expanded indications required large, multi-year studies involving thousands of patients. Research costs are often factored into pricing.
Unlike older diabetes drugs, Farxiga has proven:
These added benefits increase its perceived value in the healthcare system.
Drug prices in the United States are not directly regulated in the same way as in many other countries. Negotiations between manufacturers, pharmacy benefit managers (PBMs), and insurers significantly affect final pricing.
This depends on your medical situation.
Farxiga may be especially valuable if you have:
In these cases, Farxiga is not just a glucose-lowering drug — it is considered organ-protective therapy by major medical guidelines.
For some patients, the long-term benefits (fewer hospitalizations, slowed kidney decline) may outweigh the financial burden. For others, cost may be a barrier that requires alternative options.
If you're concerned about the Farxiga price, here are safe and appropriate actions:
This is the most important step.
Ask:
Never stop the medication abruptly without medical guidance, especially if you are taking it for heart failure or kidney disease.
Contact your insurer and ask:
Sometimes a simple prior authorization can significantly reduce cost.
Many pharmaceutical companies offer:
These can reduce monthly costs substantially if you qualify.
Depending on your diagnosis, your doctor may discuss:
Each alternative has pros and cons. The right choice depends on your full medical history.
If you have:
Cost concerns are valid — but untreated or undertreated disease can lead to:
In these cases, speak to a doctor promptly. There may be financial solutions that allow you to stay on the medication safely.
If you're researching the Farxiga price, you may already have diabetes — or be concerned you might.
Common symptoms of diabetes include:
If you're experiencing any of these symptoms and want to understand your risk level before seeing a doctor, you can use a free AI-powered Diabetes Mellitus symptom checker to evaluate your symptoms in just a few minutes and get personalized guidance on next steps.
That said, an online tool does not replace proper medical testing. A blood test is required for diagnosis.
Drug prices often decrease when:
However, significant price reductions may take time. If affordability is a concern today, practical solutions through insurance review and doctor consultation are more realistic than waiting for price changes.
Farxiga is generally well tolerated, but possible side effects include:
Seek immediate medical care if you experience:
These symptoms can be serious and require urgent evaluation.
For uninsured patients, the Farxiga price can be high — often several hundred dollars per month. For insured patients, costs vary widely.
However:
If cost is preventing you from taking your medication as prescribed, do not ignore the issue. The safest next step is to speak to a doctor about your options. Untreated diabetes, heart failure, or kidney disease can become life threatening if not properly managed.
Open communication with your healthcare provider is not only appropriate — it is essential.
Your health matters. Cost matters too. The goal is to address both responsibly and safely.
(References)
* Li H, Yang Z, Lu Y, Sun M, Wang J, Lu W, Hu R. Economic evaluation of SGLT2 inhibitors in heart failure and chronic kidney disease: A systematic review and meta-analysis. Front Pharmacol. 2023 Sep 21;14:1260388. doi: 10.3389/fphar.2023.1260388. PMID: 37780825.
* Ma J, Zhang P, Chen X, Liu R, Dong Z. Cost-effectiveness of dapagliflozin for heart failure with reduced ejection fraction and type 2 diabetes in the US. J Med Econ. 2023 Mar;26(1):285-293. doi: 10.1080/13696998.2023.2173163. PMID: 36762283.
* Kamal T, Adeli K, Lang J, Lamy V, Singh M, Cattran D. Cost-Effectiveness of Dapagliflozin for the Treatment of Chronic Kidney Disease in Canada. PharmacoEconomics. 2022 May;40(5):497-511. doi: 10.1007/s40273-022-01126-7. Epub 2022 Mar 4. PMID: 35246757.
* Zhang M, Liu J, Wang Z, Han Y, Yu R, Yang M, Li R, Yu H, Wang C. Cost-effectiveness of dapagliflozin versus standard of care for patients with heart failure with reduced ejection fraction in China. Front Pharmacol. 2023 May 3;14:1169046. doi: 10.3389/fphar.2023.1169046. PMID: 37199047.
* Ma J, Zhang P, Hu Q, Han X, Dong Z. Out-of-pocket costs for SGLT2 inhibitors and GLP-1 receptor agonists in Medicare Part D beneficiaries with type 2 diabetes. J Med Econ. 2020 Jan-Dec;23(1):33-40. doi: 10.1080/13696998.2019.1697970. Epub 2019 Nov 25. PMID: 31766914.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.